Keywords: انزولات آمید; AAWS; CRPC; Enzalutamide; Enzalutamide withdrawal; Hormone therapy;
مقالات ISI انزولات آمید (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: انزولات آمید; Castration-resistant prostate cancer; Locally advanced prostate cancer; Enzalutamide; Apalutamide; Androgen deprivation therapy;
Keywords: انزولات آمید; Abiraterone; Androgen receptor splice variant; Biomarker; Castration resistant; Enzalutamide; Prostate cancer;
Keywords: انزولات آمید; Androgen receptor variants; Androgen receptor variant 7; Castration-resistant prostate cancer; Abiraterone; Enzalutamide;
Keywords: انزولات آمید; CDK; cyclin-dependent kinase; PTMs; post-translational modifications; AR; androgen receptor; PCa; prostate cancer; PSA; prostate specific antigen; ENZ; enzalutamide; CSS; charcoal stripped serum; FBS; fetal bovine serum; ER; estrogen receptor; PR; progest
Keywords: انزولات آمید; Castration-resistant prostate cancer; Abiraterone; Enzalutamide; Metabolic syndrome; Inflammation;
Keywords: انزولات آمید; enzalutamide; metastatic castration-resistant prostate cancer; network meta-analysis; systematic literature review;
Keywords: انزولات آمید; abiraterone; bone-targeted agents; castration-resistant prostate cancer; denosumab; electronic health records; enzalutamide; zoledronic acid;
Keywords: انزولات آمید; Abiraterone; Cardiac toxicity; CRPC; Enzalutamide; HSPC;
Keywords: انزولات آمید; ARSIs; androgen receptor signaling inhibitors; AA; abiraterone acetate; AR; androgen receptor; BPH; benign prostatic hyperplasia; CNV; copy number variation; CRPC; castration resistant prostate cancer; CTC; circulating tumor cells; ctDNA; cell-free circul
Keywords: انزولات آمید; Prostate cancer; Bisphosphonates; Abiraterone acetate; Denosumab; Zoledronic acid; Enzalutamide; Radium-223;
Keywords: انزولات آمید; Abiraterone; Circulating cell-free DNA; CRPC; Enzalutamide; Resistance;
An improved and practical route for the synthesis of enzalutamide and potential impurities study
Keywords: انزولات آمید; Enzalutamide; New route; High purity; Impurity;
Keywords: انزولات آمید; Castration-resistant prostate cancer; Prostate cancer; Androgen receptor; Androgen synthesis inhibitor; Androgen deprivation therapy; Novel androgen receptor antagonist; Abiraterone; Enzalutamide;
Keywords: انزولات آمید; Sorafenib; Enzalutamide; Castration-resistant prostate cancer; Androgen receptor; Tyrosine kinase; PCa; prostate cancer; CRPC; castration-resistant prostate cancer; ADT; androgen deprivation therapy; AR; androgen receptor; Enz; enzalutamide; Sor; sorafeni
Keywords: انزولات آمید; Abiraterone; Androgen receptor degradation; Chemotherapy; CYP17 inhibition; Enzalutamide; Resistance;
Keywords: انزولات آمید; BRCA2; Circulating tumor DNA; Cell-free DNA; Liquid biopsy; Enzalutamide; Abiraterone; Castration-resistant prostate cancer; DNA repair;
Keywords: انزولات آمید; CYP450; Metabolic clearance; Drug-drug interactions; Abiraterone; Enzalutamide; Prostate cancer;
Keywords: انزولات آمید; Abiraterone; Androgen-receptor; Biomarkers; Cabazitaxel; Cell free DNA; Circulating tumor cells; Docetaxel; Enzalutamide; Metastatic castration-resistant prostate cancer; Taxanes;
Keywords: انزولات آمید; Prostate cancer; Castration resistant prostate cancer; Enzalutamide; Abiraterone; Docetaxel; Drug resistance;
Keywords: انزولات آمید; Triple negative breast cancer; Androgen receptor; Bicalutamide; Enzalutamide; Abiraterone acetate; Seviteronel;
Keywords: انزولات آمید; Prostate cancer; Castration-resistant; Treatment sequence; Abiraterone; Docetaxel; Enzalutamide; Cabazitaxel; Radium; Biomarkers;
Keywords: انزولات آمید; Prostate cancer; Abiraterone acetate; Enzalutamide; Orteronel;
Keywords: انزولات آمید; Bicalutamide; Enzalutamide; Prostate cancer; Perfluoroalkyl; Androgen receptor; Antiproliferative activity;
Keywords: انزولات آمید; Androgen receptor inhibitor; Castration-resistant prostate cancer; Enzalutamide; Long-term follow-up; MDV3100; Tolerability;
Keywords: انزولات آمید; Prostate cancer; Cabazitaxel; Abiraterone acetate; Enzalutamide; Sequential therapy
Keywords: انزولات آمید; Metastatic castration-resistant prostate cancer; Docetaxel; Young; Abiraterone acetate; Cabazitaxel; Enzalutamide;
Keywords: انزولات آمید; Enzalutamide; Abiraterone acetate; Abiraterone; Docetaxel; Castration-resistant prostate cancer
Keywords: انزولات آمید; Androgen receptor; Enzalutamide; Hormone-naïve prostate cancer; Prostate-specific antigen response;
Keywords: انزولات آمید; Abiraterone; Cabazitaxel; Enzalutamide; Metastatic castration-resistant prostate cancer; Taxanes
Keywords: انزولات آمید; Enzalutamide; Castration-resistant prostate cancer; Predictors of outcome; Bone metastasis; Bone tumor microenvironment; Adaptive feedback mechanism; Androgen receptor; Primary resistance to enzalutamide; Androgen signaling inhibition; Tissue-based resear
Keywords: انزولات آمید; Enzalutamide; Prostate cancer; MDV3100; castration resistant prostate cancer; AR targeted therapies
Keywords: انزولات آمید; Abiraterone; Antiandrogens; Drug resistance; Enzalutamide; Prostatic neoplasms; Castration resistant
Keywords: انزولات آمید; Choline-PET; Enzalutamide; Neo-adjuvant therapy
Keywords: انزولات آمید; Abiraterone; Cabazitaxel; Castration-resistant prostate cancer; Docetaxel; Enzalutamide; Therapy sequence;
Keywords: انزولات آمید; Prostate cancer; Metastatic; Castration-resistant; Cabazitaxel; Abiraterone; Enzalutamide;
Keywords: انزولات آمید; Metastatic castration-resistant prostate cancer; Consensus; Radium 223 dichloride; Abiraterone; Enzalutamide; Docetaxel; Circulating tumour cells; Sipuleucel-T; Cabazitaxel; Denosumab;
Keywords: انزولات آمید; CRPC; Novel treatments; Abiraterone; Enzalutamide; Cabazitaxel; Sipuleucel T; Radium-223;
Keywords: انزولات آمید; Castration-resistant prostate cancer; Enzalutamide; Abiraterone; Radium-223; Cabazitaxel; Docetaxel; Bone metastases;
Keywords: انزولات آمید; Prostate cancer; Castration-resistance; Sipuleucel-T; Cabazitaxel; Abiraterone; Enzalutamide; Denosumab
Keywords: انزولات آمید; Castration resistant prostate cancer; CRPC; Elderly; Abiraterone; Cabazitaxel; Sipuleucel-T; Enzalutamide; Alpharadin; Denosumab;
Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide
Keywords: انزولات آمید; Prostate cancer; Circulating tumor cell; Androgen receptor; Synaptophysin; Abiraterone; Enzalutamide;
Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan
Keywords: انزولات آمید; Abiraterone acetate; CRPC; Docetaxel; Enzalutamide; Oncological outcome;
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
Keywords: انزولات آمید; DNA repair; Germline; Mutation; Abiraterone; Enzalutamide;
Amorphous Enzalutamide - Non-isothermal recrystallization kinetics and thermal stability
Keywords: انزولات آمید; Crystallization kinetics; DSC; Enzalutamide; Thermal stability; Kinetic predictions;
Prognostic factors of oncologic outcomes in metastatic chemotherapy-naïve castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia
Keywords: انزولات آمید; Castration-resistant prostate cancer; Enzalutamide; Neutrophil-to-lymphocyte ratio; Prognosis; Biomarker;
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for â¥24 weeks in Europe
Keywords: انزولات آمید; Abiraterone acetate; Enzalutamide; Metastatic castration-resistant prostate cancer;
Validation of an LC-MS/MS method for simultaneous quantitation of enzalutamide, N-desmethylenzalutamide, apalutamide, darolutamide and ORM-15341 in mice plasma and its application to a mice pharmacokinetic study
Keywords: انزولات آمید; Enzalutamide; N-desmethylenzalutamide; Apalutamide; Darolutamide; ORM-15341; LC-MS/MS; Method validation; Mice plasma; Pharmacokinetics;
Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
Keywords: انزولات آمید; Abiraterone; Chemohterapy-naive; Enzalutamide; mCRPC; Sequential treatment;
ReviewPP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications
Keywords: انزولات آمید; PP2A; ER; AR; Tamoxifen; Enzalutamide; Breast cancer;